Inspire Advisors LLC Purchases 1,532 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Inspire Advisors LLC lifted its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 7.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 22,394 shares of the biotechnology company’s stock after acquiring an additional 1,532 shares during the period. Inspire Advisors LLC’s holdings in ADMA Biologics were worth $384,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp increased its position in ADMA Biologics by 61.4% during the 3rd quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock worth $259,970,000 after purchasing an additional 4,945,063 shares in the last quarter. Geode Capital Management LLC increased its position in ADMA Biologics by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company’s stock worth $107,606,000 after purchasing an additional 137,989 shares in the last quarter. Perpetual Ltd acquired a new position in ADMA Biologics during the 4th quarter worth approximately $62,300,000. Lord Abbett & CO. LLC acquired a new position in ADMA Biologics during the 3rd quarter worth approximately $61,858,000. Finally, Allspring Global Investments Holdings LLC increased its position in ADMA Biologics by 1,144.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock worth $51,016,000 after purchasing an additional 2,613,482 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Trading Up 6.6 %

ADMA opened at $18.50 on Thursday. ADMA Biologics, Inc. has a fifty-two week low of $5.88 and a fifty-two week high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The firm has a market capitalization of $4.37 billion, a price-to-earnings ratio of 66.07 and a beta of 0.60. The company’s 50 day moving average price is $16.67 and its two-hundred day moving average price is $17.95.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.